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ABSTRACT
Patents are a form of intellectual property rights providing exclusive rights over an invention to the inventor. The owner of a patent has the right 
to exclude making, using, or selling the new invention for a limited period, subject to a number of exceptions. For encouraging pharmaceutical 
R and D, the patent system is the best mechanism. Patent protection for pharmaceutical products and processes has become the global norm. For 
the advancement of research, the pharmaceutical patent is essential to disclosure system. The pharmaceutical industry in Indian has been growing 
in the post-trade-related aspects of intellectual property rights period. On the other hand, there are still concerns that the new patent act might 
reduce generic drug supplies and lower access to medicines in India. Since India is the major manufacturer as well supplier for generic drugs, the 
issue of access to medicines is crucial not only for India but also for other poor developing countries. Thus, the Government of India should seek 
an appropriate balance between the development of the pharmaceutical industry in Indian and the improvement of public health. The aim of this 
article is to gather some information from various sources and provides the fundamental knowledge of pharmaceutical patent to the public and 
pharmaceutical professionals toward the patent.
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INTRODUCTION
Intellectual property rights, especially patents, are highly detailed 
documents which allow inventors to register their inventions at the 
national and international level for a specified length of time. Patents 
are very important and valuable in the process of knowledge production 
and knowledge commercialization. Pharmaceutical patents are essential 
for the advancement of research. Patent protection for pharmaceutical 
products is important as compared to other industries. Pharmaceutical 
Industry in Indian become globally competitive through the world in 
present scenario because of their manufacturing capabilities with 
quality and cost-efficiency of production capacity and up gradation of 
research and development capabilities for new drugs and associated 
activities such as clinical trials and contract manufacturing.
After independence when India wanted to develop the pharmaceutical 
industry, the multinational corporations (MNCs) were invited to come 
to India to help develop the industry. Before 1972, the MNCs themselves 
were not very keen on manufacturing in India; they used their patent 
rights to prevent Indian companies from manufacturing. As a result, on 
the one hand, the industry remained underdeveloped and on the other 
hand, the monopolies led to high prices. After 1972, the monopoly power 
of the MNCs was eliminated, the industry experienced rapid growth and 
India emerged as a major player in the global pharmaceutical industry 
receiving worldwide recognition as a low-cost producer of high quality. 
In accordance with the trade-related aspects of intellectual property 
rights (TRIPS) agreement, drug product patent protection has been 
reintroduced in India since 1 January 2005 [1]. India became self-
reliant in drugs. After expiry of the patent, the MNCs are interested 
not only in the patented markets but also they are trying to grow 
aggressively in the generic segments as well [2]. Traditionally, MNCs 
have relied for their growth on patented drugs and focused mainly on 
developed country markets. When product patents were abolished in 
India in 1972, the MNCs did not stop their business in India. All the 
major MNCs decided to stay back. Considering the role that abolition 
of product patent protection played in the pharmaceutical industry 
in India, reintroduction of product patent protection since 2005 has 
crucial significance. It was decided that, though product patents have 
been introduced from 1 January 2005, a mailbox facility was put in 
place to receive and hold product patent applications. As per the TRIPS 
agreement, these applications are being processed since 1 January 2005 
for grant of patents, thus to understand the impact on the market 
structure and prices. Indian generic companies are no longer permitted 
to manufacture and market new drugs, for which patents have been 
granted in India. All new drugs are patentable in India, Under Article 
70(3) of TRIPS, a WTO member country has no obligation to provide 
patent protection for any subject matter which had fallen into the 
“public domain” before WTO came into being, i.e.,before 1 January 1995. 
Thus, any drug product patented abroad before 1995 can continue to be 
manufactured and sold in India after 1995 even though these may be 
under patent protection in other countries [3]. The aim of the present 
study is to focus on patents toward the pharmaceutical field. The paper 
provides an overview of the pharmaceutical industry toward patent.
History of India’s patent laws
The patent is a kind of intellectual property rights. The patent can be 
defined as a monopoly right conferred to the inventor who has invented 
a new product or process through his/her intellectual efforts capable of 
industrial application [4]. Patent law was passed first in India, in 1856, 
during British colonial rule. That time, the law was followed the British 
Patent Law, which was passed in 1852, that law was provided privileges 
to inventors for a period of 14-year. India was beginning to industrialize 
accordingly the patent law in the pharmaceutical industry at that time. 
At the time of independence, India’s patent regime was governed by the 
patents and Designs Act, 1911, which had provisions both for product 
and process patents. After that, it was felt that there was a need to change 
in the existing patent law since it had not helped in the promotion of 
scientific research and industrialization in the country. Immediately after 
independence, a Committee was constituted, and the Committee was 
headed by Justice (Dr.) Bakshi Tek Chand, a retired judge of the Lahore 
High Court, to undertake a comprehensive review of the working of the 
1911 Act. The Committee submitted its interim report on August 4, 1949, 
and the final report, in 1950, making recommendations for prevention of 
misuse or abuse of patent rights in India. The Committee recounted the 
patent act and advised that it should contain a clear indication that food 
and medicine and surgical and curative devices were to be made available 
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to the public at the lowest price while giving reasonable compensation 
to the patentee. Based on the Committee recommendations, some 
amendments were made in the patents and Designs Act, 1911. In 1952, 
compulsory licenses were provided for food and medicines, insecticide, 
germicide, or fungicide and for the process for producing substance or 
any invention relating to surgical or curative devices. Subsequent to that, 
one more Committee was constituted under Justice Ayyanger in 1957. 
The objective of that Committee is to specially decide (a) patents for 
chemical inventions and (b) patents for inventions relating to food and 
medicine. After examining thoroughly the contemporary law of patents 
governing inventions on chemical substances of different countries, the 
Ayyanger Committee recommended that only process claims be allowed. 
For foods and medicines, the Committee recommended that inventions 
related to foods and medicines including insecticides and fungicides 
should not be patentable as such and processes for their productions 
should alone be patentable. On the basis of these reports, the patents 
Act 1970 was enacted and came into force from 1972. The patents Act 
1970 allowed process patents for drugs, foods, and products of chemical 
reactions, but no product patents were allowed for inventions related 
to such substances. Indian pharmaceutical industry is a successful, 
high-technology-based industry that has witnessed consistent growth 
over the past three decades. The current industry players comprise 
several privately owned. During the period 1970-1994, the Indian 
pharmaceutical industry became nearly self-sufficient and one of the 
largest exporters of generic medicines. A large number of developing 
countries depend on the supply of cheaper generic medicines from India.
TRIPS agreement and Indian pharmaceutical industry
According to the TRIPS Agreement, pharmaceutical product patents 
represented one of the most divisive issues, being opposed by developing 
countries because of concerns that stronger patent protection would 
hinder access to drugs and prevent the development of a domestic 
pharmaceutical industry. The TRIPS agreement forced developing country 
members of the WTO to grant patents with a statutory lifetime of 20-years 
from the patent application also to pharmaceutical compounds [5]. 
Despite the strengthening of intellectual property rights brought by 
TRIPS, some developing countries continue to apply more restrictive 
approach than developed countries to the granting of pharmaceutical 
patents. TRIPS requires the availability of patent protection for the 
processes as well as products in “all fields of technology” the agreement 
provides countries with substantial freedom to define the standards of 
patentability. Developing countries, like India (India’s patents act of 2005 
(Amended)), have used this freedom to restrict the granting of so-called 
secondary pharmaceutical patents. As opposed to primary patents which 
protect an active ingredient directly, secondary patents protect a range 
of chemicals related to an active ingredient (such as crystalline forms 
of the original compound), methods of use, formulations, dosages, etc. 
For pharmaceuticals, data exclusivity provides protection to the clinical 
data generated by innovator companies to prove the safety and efficacy 
of their products. Pharmaceutical company those are innovator for any 
product are required to submit clinical test data relating to safety and 
efficacy to national regulatory authorities to obtain market approval for 
new drugs. Pharmaceutical company those are manufacturing generic 
products, i.e. Generic companies are not required to conduct their own 
clinical testing and submit their own test data to gain market approval.
Brief summary on patents
Drugs patented after 1 January 1995 can be classified into the following 
categories:
1. New chemical entities (NCEs) or new molecular entities, and new 
biological entities (NBEs) patented after 1995
2. NCEs/NBEs developed before 1995 but with patents after 1995 and 
satisfy
a. New formulations and compositions
b. New combinations
c. New chemical derivatives (salts, esters, etc.,).
The government has granted patent, which is an exclusive right, 
given to the applicant for an invention. The patent can be applied by 
the inventor or any other person/company assigned by the inventor. 
Patentee includes to provide rights to license others for the purpose of 
making, using, or selling the patented invention. The patent is a contract 
between an applicant/inventor and the government, wherein the 
government provides right of protection of the invention for a limited 
period. Patenting provides a strategy for protecting inventions without 
keeping the invention secret. For the technical problem of a patent, 
patent offers provide technical solution. Inventions which satisfies 
certain conditions known as criteria of patentability. Patent is granted 
only to that inventor. Patents have a limited term of 20 years counted 
from the date of filing the patent application. The patent is a territorial 
right; thus, it can be enforced only in the country where it is granted. 
Patent cooperation treaty (PCT) provides a route to file an international 
patent application through with patent can be filed in a large number 
of countries through a single patent application. However, after filing 
the PCT application, grant of patent remains under the discretion of the 
individual patent office only.
Patents are distinguished as primary patent and secondary patent.
Primary patent: Patents, those are usually filed already during the 
research phase in the development of a new drug, in the pharmaceutical 
industry are called primary patents. In that primary patent, patents 
give on the active ingredients. These early patents are filed to protect 
potential active ingredients that form the basis of the new drug. Since 
the early stages of drug development are characterized by an enormous 
amount of uncertainty that 1 in 5,000-10,000 test active ingredients 
results in a successful drug, early patent filings in this, in that case, 
many of these filings will either not be pursued, or if granted, will never 
be related to a marketed drug.
Secondary patents: After drug development, patents are filed on 
other aspects of active ingredients such as different dosage forms, 
formulations, and production methods [6,7].
Criteria of patentability
Some requirements should be full filled during patent application, 
to achieve the status of a patent. Broadly, the invention itself has 
to meet three main requirements: (i) Novelty, (ii) inventive step, 
and (iii) industrial applicability (needless to say that deadlines and 
fees might apply). The first requirement, novelty, means that only 
new inventions can be patented. If an invention is publicly disclosed 
before a patent application is filed, it will not be able of protection. 
This previous disclosure is known as either prior art or state of the 
art of the technological field. The second requirement by definition is 
reached whenever an invention is not obvious to someone with a good 
knowledge and experience in the corresponding technical field. Finally, 
the requirement of industrial applicability implies the invention to be 
possible to be carried out in practice.
The invention lies in one of the following categories: (i) Products, 
(ii) processes or methods, and (iii) machines. Although a machine can 
also be a product if a firm makes machines for sale, it is better to keep 
them in different categories because of their characteristics in terms of 
enforcement [8]. For product, if a company invents a product, it is likely 
that it will attempt to profit from it, and therefore, that product will be 
available in the market soon. If the invention is the machine, however, 
it does not necessarily mean that it will be launched on the market, 
especially if selling machines is not a firm’s core business. A company 
can keep in secrecy the apparatus to make a product since it is unlikely 
that competitors will have access to it and then copy it. It also means 
that a machine patent tends to be more difficult to prove infringement 
than a product patent because the latter can be found easily in the 
marketplace. Processes or methods would be procedures responsible 
for making a product. Alike machines, processes may never be accessed 
by competitors. It means that process patents tend to be more difficult 
to enforce. In general, product patents are the most valuable followed 
by process and machines patents. The scope of a patent is basically 
described by its claims, which are sentences at the end of each patent 
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that describe the invention. They may pose a threshold to others keen 
on performing the invention. A patent application may be filed in a 
national patent office or supra-national patent offices, such as the world 
intellectual property organization (WIPO). The date when a patent 
application is first filed is labeled the priority date. An applicant may 
filled for patent in as per his own choice; once a patent application is 
filed it will be either examined or registered. Latter case implies that a 
patent will automatically be granted, and its validity will only be tested 
in the court. The patent office, where the applicant applies for patent, 
will request to deposit the fee to be paid on filing. Within 12 months, 
the applicant must request and pay the corresponding fee for the 
preliminary examination - to check whether the application is able to 
proceed - and search - to look for any relevant documents which may 
invalidate or restrict what is claimed in a patent application. There is 
no need to wait 12 months to request preliminary examination and 
search; it can be done on filing since the priority date is the one taken 
into account to determine prior art. Unless the one who applied for a 
patent (applicant) withdraws his/her application, or simply abandon 
it, the invention will be disclosed soon. An invention is kept secret until 
the 18th month from the priority date, and then the patent application is 
published. From that point, the disclosed invention also becomes prior 
art against any application filed later. From that point, the disclosed 
invention also becomes prior art against any application filed later. The 
date when a patent application is first filed with a patent office (priority 
date) is of crucial importance for the subsequent prosecution of the 
application. It is the date, which is used to give priority to an invention. 
It means that if more than one institution, or individual, seek protection 
for the same invention, a patent might be granted for the one who 
applied first. Patent systems operate at single country levels (e.g., the UK 
and US) and at supra-national levels (e.g., European Patent Office and 
WIPO), but there is no such a thing as an international patent covering 
all countries in the world. Even if a company chooses to use one of those 
supra-national systems, it has to designate all countries of interest (as 
long as the chosen countries have signed any treaty agreeing with the 
rules of the system) and pay the corresponding fees [9].
Description
Patents play an integral role in pharmaceutical research and 
development of developed and developing countries. An invention 
is any new or useful process, machine, article of manufacture, or 
composition of matter. An improvement on any of these items also can 
be an invention. Patent rights are territorial in nature and exist only 
in the national jurisdictions in which the patentee has applied for and 
received recognition of his property rights. The presence of strong 
patent protection combined with the concurrent ability to assure a 
profitable return on investment means that commercial pharmaceutical 
research and development is being overwhelmingly directed at 
producing drugs which will meet patient needs in these developed 
as well as developing countries. Patent protection for pharmaceutical 
products in the developing country can help to encourage the 
development of new medicines for diseases that affect these countries, 
by providing protection for the investments that need to be made by the 
pharmaceutical companies. Pharmaceutical companies often maintain 
that patent protection for drugs ensures that they are able to invest 
billions of dollars into the development of new products, by making 
sure that they will be able to take advantage of the sales. A patent claim 
relating to a pharmaceutical product may relate to an active ingredient 
as such independently of or jointly with formulations, salts, prodrugs, 
and isomers, or cover any of these subject matters separately. It may 
also solely cover a manufacturing process or include both a process 
and a product. In some countries, as noted below, use-related claims 
are admissible [10]. The Indian pharmaceutical industry has achieved 
self-sufficiency in pharmaceutical production and emerged as one 
of the largest drug exporters in the world. India is one of the major 
drug-producing countries. The industry has become one of the major 
drug exporters since the late 1980s and showed promise of its global 
competitiveness. The Indian pharmaceutical industry continues to 
expand its presence across the world.
CONCLUSIONS
A patent is considered a major incentive for technological development, 
both for being an official document that grants legal protection to 
the invention and for being the greatest source of information on 
technological innovation in the world. Since pharmaceutical industry 
based on products and processes, have now assumed an increasing 
importance in the global economy, there is a definite need to globally 
harmonize policies and procedure in respect of protection of 
intellectual property rights in view of the fact that enterprises engaged 
in research will make investment only if strong legal protection is 
available for the result of their research. India has begun to see some 
positive results as awareness of the need for greater IP protection has 
increased. Educating all the pharma professionals from manufacturer 
to innovators to industry players is vital for achieving the benefits of IP 
regime as well as for standing strong among global competing players.
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